Genomic Valley Biotech

Genomic Valley Biotech Liabilities

Delisted·Sep 16, 2026

The The Liabilities of Genomic Valley Biotech (539206.BO) as of Oct 21, 2026 is 4.58 M INR. In the previous year, The Liabilities was 7.92 M INR — a change of -42.09% (lower).

Liabilities

4.58 MINR

YoY

-42.09%

Last updated:

In 2025, Genomic Valley Biotech's total liabilities amounted to 4.58 M INR, a -42.09% difference from the 7.92 M INR total liabilities in the previous year.

The Genomic Valley Biotech Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2022
9.19 M INR
Jan 1, 2023
8.94 M INR
Jan 1, 2024
7.92 M INR
Jan 1, 2025
4.58 M INR
The Genomic Valley Biotech Liabilities history
YEARLiabilitiesYoY
4.58 MINR-42.09%
7.92 MINR-11.40%
8.94 MINR-2.75%
9.19 MINR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Genomic Valley Biotech Stock analysis

What does Genomic Valley Biotech do? Genomic Valley Biotech Ltd, identified by the ticker symbol 539206.BO and the ISIN code INE574D01010, is an Indian corporate entity established within the biotechnology and life sciences sector. The company maintains its primary operational headquarters in Bahadurgarh, a city located in the state of Haryana, India. This geographical positioning places the firm within a significant industrial and technological hub in northern India, facilitating its business operations and strategic partnerships within the regional ecosystem. The organization entered the public equity markets through an Initial Public Offering that was officially executed on July 10, 2015. This milestone marked a critical transition in the company's corporate history, allowing it to raise capital from public investors and increase its visibility within the financial markets. The listing on the Bombay Stock Exchange under the specified ticker provides a mechanism for public trading and valuation of the company's shares. While specific details regarding its industry classification and sector categorization are not explicitly defined in the available reference data, the company's name and operational focus imply a specialization in genomic technologies and biotechnological solutions. The corporate profile is further accessible through its official digital presence at http://www.genomicvalley.com/, where stakeholders and interested parties can obtain additional information regarding its business activities, corporate governance, and financial performance. As a publicly traded entity, Genomic Valley Biotech Ltd is subject to the regulatory frameworks and disclosure requirements mandated by Indian securities regulators. The company's journey from its foundational establishment to its public listing in 2015 represents a structured growth trajectory aimed at expanding its reach and capabilities in the competitive biotech landscape. Investors and analysts monitoring the Indian market may track the company's performance through its stock ticker, utilizing the ISIN for precise identification in global financial databases. The lack of explicit sector or industry tags in the provided data does not diminish the company's operational identity, which remains anchored in the scientific and technological advancements associated with genomics and biotechnology. The headquarters in Bahadurgarh serves as the central node for administrative, research, and strategic decision-making processes, supporting the company's ongoing initiatives and market engagements. Genomic Valley Biotech is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing Genomic Valley Biotech's Liabilities

Genomic Valley Biotech's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Genomic Valley Biotech's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Genomic Valley Biotech's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Genomic Valley Biotech's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Genomic Valley Biotech’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Genomic Valley Biotech stock

The Liabilities of Genomic Valley Biotech is 4.58 M INR in 2025.

The Liabilities of Genomic Valley Biotech changed from 7.92 M INR to 4.58 M INR, representing a -42.09% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities Genomic Valley Biotech since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's INR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's Genomic Valley Biotech historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Genomic Valley Biotech

All Key Metrics — Genomic Valley Biotech